<DOC>
	<DOCNO>NCT01086852</DOCNO>
	<brief_summary>To primary efficacy variable assess presence absence excessive blood loss surgery . The secondary efficacy endpoint follow : 1 . A subjective overall assessment investigator FACTOR X control bleed surgery . 2 . The incidence bleed episode treatment FACTOR X subject risk post-operative bleeding , include location duration . 3 . Incremental recovery FX : C FX : Ag pre-surgery bolus infusion . 4 . Assessment FX : C FX : Ag level day post-surgery . 5 . Assessment cumulative weight-adjusted dos FACTOR X measure FX : C ( IU/kg body weight ) administer subject maintain haemostasis . 6 . Assessment cumulative dos FACTOR X measure FX : C ( IU ) administer subject maintain haemostasis . 7 . Amount weight-adjusted FACTOR X measure FX : C ( IU/kg body weight ) administer daily ( day surgery post-operative day ) maintain haemostasis .</brief_summary>
	<brief_title>Safety &amp; Efficacy BPL 's High Purity FACTOR X Treatment Factor X Deficient Subjects Undergoing Surgery</brief_title>
	<detailed_description>To investigate safety efficacy FACTOR X administer bolus infusion prevent bleed achieve haemostasis factor X deficient subject undergoing surgery .</detailed_description>
	<mesh_term>Factor X Deficiency</mesh_term>
	<criteria>Subjects least 12 year age date write informed consent/assent . Subjects give write informed consent , subject age 1217 year ( inclusive ) , give write assent whose parent/guardian give write informed consent . Subjects hereditary mild severe Factor X deficiency ( &lt; 20 % basal FX activity ) , include previously untreated subject OR currently treat Fresh Frozen Plasma ( FFP ) , Prothrombin Complex Concentrate ( PCC ) factor IX/X concentrate prophylaxis demand . Subjects undergo surgery investigator believe factor X concentrate require due prior history unusual bleeding either spontaneously surgery trauma absence treatment factor X contain product . Pregnant subject undergo obstetric delivery ( include Caesarean surgery vaginal delivery ) may enter study . Female subject childbearing potential must negative result human chorionic gonadotropinbased pregnancy test . If female subject becomes sexually active , must practice contraception use method proven reliability duration study . Subjects require expected take factor X contain medication surgery . Subjects history inhibitor development FX detectable inhibitor FX ( ≥0.6 BU ) NijmegenBethesda assay screen . Obtaining FX inhibitor result screen mandatory subject undergo emergency surgery local laboratory unable perform analyse prior surgical procedure . Subjects thrombocytopenia ( platelet &lt; 50 x 109/L ) . Subjects clinically significant renal disease ( creatinine &gt; 200µmol/L ) . Subjects clinically significant liver disease ( ALT level great three time upper limit normal ) . Subjects know coagulopathy thrombophilia . Subjects currently participate participate another trial within last 30 day , exception BPL Factor X PK study ( protocol number Ten01 ) . Female subject lactate . Subjects know suspected hypersensitivity investigational medicinal product excipients . Subjects know abused chemical drug within past 12 month . Subjects history unreliability noncooperation .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Factor X deficiency</keyword>
	<keyword>surgery</keyword>
	<keyword>Factor X deficiency subject require surgery</keyword>
</DOC>